Aerovate Therapeutics Inc (AVTE)
$1.92
+0.03
(+1.59%)▲
Performance
- $1.86$1.96$1.92
3.12%
Downside
Day's Volatility :4.86%
Upside
1.79%
- $1.25$32.42$1.92
34.9%
Downside
52 Weeks Volatility :96.14%
Upside
94.08%
Returns
| Period | Aerovate Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -91.17% | 6.5% | 0.0% |
6 Months | -89.14% | 7.1% | 0.0% |
1 Year | -88.52% | 9.8% | 0.0% |
3 Years | -86.09% | 14.2% | -20.2% |
Highlights
Market Capitalization | 51.7M |
Book Value | $3.26 |
Earnings Per Share (EPS) | -3.03 |
Wall Street Target Price | 2.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -47.79% |
Return On Equity TTM | -80.58% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -88.3M |
Diluted Eps TTM | -3.03 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.94 |
EPS Estimate Next Year | -1.6 |
EPS Estimate Current Quarter | -0.76 |
EPS Estimate Next Quarter | -0.75 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 17.19%
Technicals Summary
Sell
Neutral
Buy
Aerovate Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aerovate Therapeutics Inc | 33.33% | -89.14% | -88.52% | -86.09% | -87.23% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aerovate Therapeutics Inc | 0.88 | NA | NA | -2.94 | -0.81 | -0.48 | NA | 3.26 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aerovate Therapeutics Inc | Buy | $51.7M | -87.23% | 0.88 | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Aerovate Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 150.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 272.6%
Institutional Holdings
RA Capital Management, LLC
28.69%Sofinnova Ventures
13.05%TCG Crossover Management, LLC
7.64%Baker Bros Advisors LP
5.83%Cormorant Asset Management, LLC
3.71%Great Point Partners LLC
3.08%
Company Information
aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.
Organization | Aerovate Therapeutics Inc |
Employees | 51 |
CEO | Mr. Timothy P. Noyes M.B.A. |
Industry | Healthcare |
